Slide 1: Result presentation: Q1/2021
6 May 2021, Seppo Kopsala, CEO / Lars Lindqvist, CFO Result presentation: Q1/2021
Slide 2: Highlights
Highlights OPT@MED
Slide 3: Highlights Q1-2021
Devices segment’s revenue Revenue increased 30%. At increased by 49% driven by 1. comparable exchange rates, 4. strong demand in China and a revenue grew by 30.4% positive start in our US camera sales The key driver for the strong Highlights Q1-2021 growth was the increase in Software segment contin
Slide 4: Focus areas
Focus areas China: • Channel reform started to expand our sales network to cover both a larger geographic area and more customer segments • Cooperation started with a very well-known Chinese company focusing on pharmaceutical and medical devices sales USA: • Strong sales in the US market compared to
Slide 5: COVID-19 Coronavirus
COVID-19 Coronavirus • COVID-19 Coronavirus pandemic continues; vaccinations progressing • What does it mean to Optomed: • Devices segment sales continue to be affected as the market standard sales model is face-to-face: adjusting to virtual sales efforts • OEM sales have been slower than last year,
Slide 6: Q1/2021 Financial highlights (KEUR)
Q1/2021 Financial highlights (KEUR) Q1/2021 Q1/2020 Change Revenue 3,944 3,034 30.0% Gross profit 1) 2,577 1,977 30.3% Gross margin 2) 65.3% 65.2% 0.1 bps Adjusted EBITDA -315 -575 45.37% Adjusted EBITDA margin -8.0% -19.0% 11.0 bps Net profit/ loss -616 -1,250 50.7% Earnings per share -0.05 -0.12 6
Slide 7: Devices segment highlights
Devices segment highlights
Slide 8: Devices segment highlights
Revenue grew by 49% mainly Q1/2021 Q1/2020 Change driven by demand for handheld 1. cameras in China, boosted by Devices segment highlights demand in the US Revenue 1,447 974 48.6% Gross margin increased due to higher share of Optomed branded 2. products. Q1’20 was negatively Gross profit 842 396 112
Slide 9: Software segment highlights
Software segment highlights
Slide 10: Software segment highlights
The Software segment Q1/2021 Q1/2020 Change continued its solid performance 1. - Revenue, Gross profit and Software segment highlights EBITDA increased Revenue 2,497 2,060 21.2% Gross margin decreased due to 1,734 1,581 9.7% 2. a different product mix in sales Gross profit compared to previous year
Slide 11: Outlook 2021
Outlook 2021
Slide 12: Outlook 2021
Outlook 2021 Optomed expects its full year 2021 revenue to grow strongly compared to 2020 (Announced 8 April 2021)
Slide 13: Financial targets
Financial targets Revenue Growth Adjusted EBITDA Optomed’s medium-term target is to deliver Optomed’s target is to prioritise a double-digit annual organic revenue investments in the organisation to growth. In the long-term Optomed’s target support growth in the medium-term and is to deliver an aver
Slide 14: Balance sheet
Balance sheet 31.3.2021 31.3.2020 Balance sheet ASSETS Goodwill 4,256 4,256 Development costs 5,842 5,311 • Equity ratio of 64.2 (66.0) percent Other intangible assets 2,718 3,090 Total intangible assets 12,816 12,657 • Total borrowings of EUR 6.4 (6.6) Total tangible assets 1,501 1,369 million. EUR
Slide 15: Cash flow
Q1/2021 Q1/2020 Cash flow Loss for the financial year -616 -1,250 Cash flows before change -34 -509 in net working capital Change in net working capital -223 -2,212 • Cash flow from operating activities Cash flows before finance items -257 -2,721 amounted to EUR -0.3 (-2.9) million Cash flows from f
Slide 16: Optomed's mission is to prevent blindness
“ Optomed’s Expansion into new geographical markets mission is to prevent blindness by improving access to eye screening Opening new customer segments: primary care globally Bringing AI-integrated health screening to the market
Slide 17: Optomed Plc contact details
Optomed Plc. Yrttipellontie 1, 90230 Oulu, Finland Tel: +358 20 741 3380 • investors@optomed.com www.optomed.com